Search results
Linda Avey ( née Bahnson [not verified in body]) is an American biologist and entrepreneur. She is known for co-founding 23andMe, a consumer genetic data company. [1] [2] Early life. Avey was born Linda Bahnson in 1960, in South Dakota, United States. [citation needed] .
- Augustana University (1982)
- Co-founder of 23andMe, Precise.ly, Inc.
Nov 30, 2023 · Linda Avey, co-founder of 23andMe and Humain Ventures, is appointed to the Board of Directors of the Human Immunome Project (HIP), a nonprofit organization that decodes and models the human immune system. HIP aims to use AI to improve health and decrease healthcare costs worldwide.
Nov 27, 2013 · Watch an interview with Linda Avey, co-founder of 23andMe, about the advantages and challenges of open science. She also comments on other open science projects presented at the 2011 Open Science Summit.
- Brian Malow
Linda Avey. Linda Avey is a founding general partner at Humain Ventures, an Austin, TX-based venture capital firm investing at the intersection of AI and the bioeconomy. Linda has been at the forefront of the digital health movement. As the visionary founder of 23andMe in 2006, her mission to assemble a research repository of genetic and ...
Linda Avey, Paul Cusenza and Anne Wojcicki founded 23andMe in 2006 to offer genetic testing and interpretation to individuals. Investment documents from 2007 also suggest that 23andMe hoped to develop a database to pursue research efforts.
- April 2006; 17 years ago
- South San Francisco, California, United States
- 816 (2023)
Oct 12, 2017 · Wojcicki founded 23andme in 2006 with Linda Avey and Paul Cusenza with a goal of upending conventional models of health care. The following year, it received $8.95 million from a number of high ...
Linda Avey is a founding Managing Partner of Humain Ventures, investing at the intersection of AI and life sciences.. She was at the forefront of the digital health movement as a founder of 23andMe and the first independent board director of Rock Health. Her interests span precision health, AI-driven drug development, and the emergence of ...
Related searches
